Trial NCT04665115

View at ClinicalTrials.gov 
Org. Study IDs: ACCRU-LY-2001
Secondary IDs: ACCRU-LY-2001 NCI-2020-11785 P30CA015083

Last trial update was posted on 2022-08-03

MeSH Interventions

Ibrutinib

MeSH Conditions

COVID-19 Communicable Diseases Infections Laboratory Infection Leukemia Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Lymphoma Lymphoma, B-Cell Lymphoma, Mantle-Cell Waldenstrom Macroglobulinemia

Other Conditions

Asymptomatic COVID-19 Infection Laboratory-Confirmed B-Cell Neoplasm Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Small Lymphocytic Lymphoma Symptomatic COVID-19 Infection Laboratory-Confirmed

Stopping Reasons

Permanently closed 11/19/201. The widespread availability of COVID vaccination, the projected decline in infection rates, and the increasing use of non-ibrutinib containing BTKi therapy, we have not been able to get support for this study

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID